Skip to main content
. Author manuscript; available in PMC: 2021 Dec 21.
Published in final edited form as: Anticancer Res. 2021 Dec;41(12):5919–5933. doi: 10.21873/anticanres.15411

Figure 5.

Figure 5.

ELISA protein expression quantification in MDA-MB-231 and MDA-MB-468 triple negative breast cancer cells (TNBC). MDA-MB-231 and MDA-MB-468 TNBC cells were treated with diallyl trisulfide (DATS) (75 μM), TNF-α (40 ng/ml), the combination of DATS (75 μM)+TNF-α (40 ng/ml) or left untreated. CCL2/MCP-1 (A, B) and IL-6 (C, D) protein expression were assayed by ELISA. Each data point represents the mean±S.E.M. of three independent experiments (n=3). Statistically significant differences between TNF-α vs. treatments were evaluated by a one-way ANOVA, followed by Dunnett’s multiple comparison test with *p<0.05 and ***p<0.001. NS: Non-significant.